Pulmonary Arterial Hypertension - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Pulmonary Arterial Hypertension - Pipeline Insight, 2021,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pulmonary Arterial Hypertension: Overview
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test”, which measures how far an individual can walk in that time period. Treatment for PAH includes prostaglandins, endothelin receptor antagonists, phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies.
'Pulmonary Arterial Hypertension - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Arterial Hypertension pipeline landscape is provided which includes the disease overview and Pulmonary Arterial Hypertension treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Arterial Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Pulmonary Arterial Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Arterial Hypertension Emerging Drugs
Further product details are provided in the report……..
Pulmonary Arterial Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Arterial Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
Pulmonary Arterial Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Arterial Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Arterial Hypertension drugs.
Pulmonary Arterial Hypertension Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pulmonary Arterial Hypertension - Pipeline Insight, 2021,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pulmonary Arterial Hypertension: Overview
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test”, which measures how far an individual can walk in that time period. Treatment for PAH includes prostaglandins, endothelin receptor antagonists, phosphodiesterase Type 5 inhibitors. Other treatments such as anticoagulants, diuretics, and oxygen may be used to treat PAH as supportive therapies.
'Pulmonary Arterial Hypertension - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Arterial Hypertension pipeline landscape is provided which includes the disease overview and Pulmonary Arterial Hypertension treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Arterial Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Arterial Hypertension.
This segment of the Pulmonary Arterial Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Arterial Hypertension Emerging Drugs
- Sotatercept: Acceleron Pharma
- LIQ861: Liquidia Technologies
Further product details are provided in the report……..
Pulmonary Arterial Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Arterial Hypertension drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pulmonary Arterial Hypertension
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pulmonary Arterial Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Arterial Hypertension therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Arterial Hypertension drugs.
Pulmonary Arterial Hypertension Report Insights
- Pulmonary Arterial Hypertension Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pulmonary Arterial Hypertension drugs?
- How many Pulmonary Arterial Hypertension drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Arterial Hypertension?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck Sharp & Dohme
- Acceleron Pharma
- Liquidia Technologies
- Gossamer Bio
- Resverlogix
- PhaseBio Pharmaceuticals
- Pharmosa BioPharm
- Complexa
- Gmax Biopharm Australia
- Mezzion
- Radikal Therapeutics
- Galectin Therapeutics
- Altavant Sciences
- Ribomic
- MK-5475
- Sotatercept
- LIQ861
- GB-002
- Apabetalone
- PB1046
- L-606
- CXA-10
- GMA-301
- Udenafil
- R107
- Belapectin
- Rodatristat ethyl
- RBM-011
Introduction
Executive Summary
Pulmonary Arterial Hypertension: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sotatercept: Acceleron Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
GB-002: Gossamer Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Apabetalone: Resverlogix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
R107: Radikal Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pulmonary Arterial Hypertension Key Companies
Pulmonary Arterial Hypertension Key Products
Pulmonary Arterial Hypertension- Unmet Needs
Pulmonary Arterial Hypertension- Market Drivers and Barriers
Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
Pulmonary Arterial Hypertension Analyst Views
Appendix
Executive Summary
Pulmonary Arterial Hypertension: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sotatercept: Acceleron Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
GB-002: Gossamer Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Apabetalone: Resverlogix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
R107: Radikal Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pulmonary Arterial Hypertension Key Companies
Pulmonary Arterial Hypertension Key Products
Pulmonary Arterial Hypertension- Unmet Needs
Pulmonary Arterial Hypertension- Market Drivers and Barriers
Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
Pulmonary Arterial Hypertension Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Pulmonary Arterial Hypertension
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pulmonary Arterial Hypertension
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pulmonary Arterial Hypertension
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pulmonary Arterial Hypertension
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
